Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) has announced the passing of Ernest Mario, Ph.D., former Chairman of the Board of Directors, at the age of 86. Dr. Mario served as Soleno's Chairman from 2007 through August 2024. The company expressed deep sadness and extended condolences to Dr. Mario's family.
Dr. Mario had a distinguished career in the pharmaceutical industry spanning decades. He held key positions at companies such as Strasenburgh Laboratories, SmithKline, Squibb Corp., and Glaxo plc. As CEO and Deputy Chairman of Glaxo, he oversaw the launch of five major brands, leading the company to become the second-largest pharmaceutical company globally. He later served as CEO of Alza and Chairman and CEO of Reliant Pharmaceuticals.
Soleno Therapeutics acknowledged Dr. Mario's significant contributions to the development of new treatments for various diseases and his commitment to the company's success.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) ha annunciato la scomparsa di Ernest Mario, Ph.D., ex Presidente del Consiglio di Amministrazione, all'età di 86 anni. Il Dr. Mario ha ricoperto il ruolo di Presidente di Soleno dal 2007 fino ad agosto 2024. L'azienda ha espresso profondo dolore e ha porgendo le proprie condoglianze alla famiglia del Dr. Mario.
Il Dr. Mario ha avuto una carriera illustre nell'industria farmaceutica che si è estesa per decenni. Ha ricoperto posizioni chiave in aziende come Strasenburgh Laboratories, SmithKline, Squibb Corp. e Glaxo plc. In qualità di CEO e Vice Presidente di Glaxo, ha supervisionato il lancio di cinque marchi principali, portando l'azienda a diventare la seconda più grande azienda farmaceutica a livello globale. In seguito, è stato CEO di Alza e Presidente e CEO di Reliant Pharmaceuticals.
Soleno Therapeutics ha riconosciuto i significativi contributi del Dr. Mario nello sviluppo di nuovi trattamenti per varie malattie e il suo impegno per il successo dell'azienda.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) ha anunciado el fallecimiento de Ernest Mario, Ph.D., ex Presidente de la Junta Directiva, a la edad de 86 años. El Dr. Mario ocupó el cargo de Presidente de Soleno desde 2007 hasta agosto de 2024. La compañía expresó su profundo pesar y ofreció sus condolencias a la familia del Dr. Mario.
El Dr. Mario tuvo una carrera distinguida en la industria farmacéutica que abarcó varias décadas. Ocupó puestos clave en empresas como Strasenburgh Laboratories, SmithKline, Squibb Corp. y Glaxo plc. Como CEO y Vicepresidente de Glaxo, supervisó el lanzamiento de cinco marcas principales, llevando a la compañía a convertirse en la segunda empresa farmacéutica más grande del mundo. Más tarde, fue CEO de Alza y Presidente y CEO de Reliant Pharmaceuticals.
Soleno Therapeutics reconoció las contribuciones significativas del Dr. Mario al desarrollo de nuevos tratamientos para diversas enfermedades y su compromiso con el éxito de la empresa.
솔레노 테라퓨틱스, Inc. (NASDAQ: SLNO)는 Ernest Mario, Ph.D.의 별세 소식을 전했습니다. 그는 이사회 의장을 역임했으며, 86세의 나이로 세상을 떠났습니다. Mario 박사는 2007년부터 2024년 8월까지 솔레노의 의장직을 맡았습니다. 회사는 깊은 슬픔을 표하며 Mario 박사의 가족에게 애도와 위로를 전했습니다.
Mario 박사는 수십 년에 걸쳐 제약 산업에서 뛰어난 경력을 쌓았습니다. 그는 Strasenburgh Laboratories, SmithKline, Squibb Corp., Glaxo plc와 같은 회사에서 주요 직책을 역임했습니다. Glaxo의 CEO 및 부회장으로서 그는 다섯 개의 주요 브랜드 출범을 감독하며 회사를 세계에서 두 번째로 큰 제약 회사로 성장시켰습니다. 이후, 그는 Alza의 CEO 및 Reliant Pharmaceuticals의 회장 겸 CEO로 활동했습니다.
솔레노 테라퓨틱스는 Mario 박사가 다양한 질병에 대한 새로운 치료법 개발에 기여한 바와 회사의 성공을 위한 그의 헌신을 인정했습니다.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) a annoncé le décès de Ernest Mario, Ph.D., ancien Président du Conseil d'Administration, à l'âge de 86 ans. Le Dr Mario a été Président de Soleno de 2007 à août 2024. L'entreprise a exprimé sa profonde tristesse et a présenté ses condoléances à la famille du Dr Mario.
Le Dr Mario a eu une carrière distinguée dans l'industrie pharmaceutique qui s'est étendue sur plusieurs décennies. Il a occupé des postes clés dans des entreprises telles que Strasenburgh Laboratories, SmithKline, Squibb Corp. et Glaxo plc. En tant que PDG et Vice-président de Glaxo, il a supervisé le lancement de cinq grandes marques, propulsant l'entreprise en tant que deuxième plus grande société pharmaceutique au monde. Par la suite, il a été PDG d'Alza et Président et PDG de Reliant Pharmaceuticals.
Soleno Therapeutics a reconnu les contributions significatives du Dr Mario au développement de nouveaux traitements pour diverses maladies ainsi que son engagement envers le succès de l'entreprise.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) hat den Tod von Ernest Mario, Ph.D., ehemaliger Vorsitzender des Vorstands, im Alter von 86 Jahren bekannt gegeben. Dr. Mario war von 2007 bis August 2024 Vorsitzender von Soleno. Das Unternehmen drückte sein tiefes Bedauern aus und sprach der Familie von Dr. Mario sein Beileid aus.
Dr. Mario hatte eine herausragende Karriere in der pharmazeutischen Industrie, die sich über Jahrzehnte erstreckte. Er bekleidete Schlüsselpositionen bei Unternehmen wie Strasenburgh Laboratories, SmithKline, Squibb Corp. und Glaxo plc. Als CEO und stellvertretender Vorsitzender von Glaxo überwachte er die Einführung von fünf wichtigen Marken und machte das Unternehmen zur zweitgrößten Pharmafirma weltweit. Später war er CEO von Alza sowie Vorsitzender und CEO von Reliant Pharmaceuticals.
Soleno Therapeutics würdigte die bedeutenden Beiträge von Dr. Mario zur Entwicklung neuer Behandlungen für verschiedene Krankheiten sowie sein Engagement für den Erfolg des Unternehmens.
- None.
- None.
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced with deep sadness the passing of former Chairman of the Board of Directors, Ernest Mario, Ph.D, at the age of 86 years. Dr. Mario served as the Soleno’s (formerly Capnia’s) Chairman from 2007 through August 2024.
"On behalf of the Board of Directors and the entire Soleno family, we extend our deepest condolences to Dr. Mario’s family,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “Dr. Mario’s decades-long commitment to the development of new treatments for patients with a diverse variety of diseases has few parallels. He was an empathic human and a valuable strategic resource committed to the success of Soleno. We are grateful for his extensive contributions over the years. He will be greatly missed."
Dr. Mario’s career in the pharmaceutical industry began in 1966 as a researcher at Strasenburgh Laboratories in Rochester, NY. He later held various management positions within SmithKline and Squibb Corp. and was elected to the Squibb Board in 1984. He joined Glaxo plc in 1986, and subsequently served as Chief Executive and Deputy Chairman, during which time he oversaw the launch of five major brands as Glaxo became the second-largest pharmaceutical company in the world. In 1993, Ernie joined Alza Corporation as CEO, where he led what was then one of the largest mergers in pharmaceutical history with Johnson & Johnson. He went on to serve as Chairman and CEO of Reliant Pharmaceuticals, which was acquired by GlaxoSmithKline. In addition, he served on numerous public and private boards over his career.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the timing of any regulatory process or ultimate approvals and determining a path forward for DCCR for the treatment of PWS. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with the FDA’s review of our NDA, market conditions, as well as risks and uncertainties inherent in Soleno’s business, including those described in the company's prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
FAQ
Who was Ernest Mario and what was his role at Soleno Therapeutics (SLNO)?
What notable positions did Ernest Mario hold in the pharmaceutical industry?
What major achievement did Ernest Mario oversee at Glaxo plc?
When did Ernest Mario pass away and at what age?
